A single 1-g preoperative dose of dried ginger powder × Reduction of nausea incidence within 24 postoperative hours

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Met	Full text not readStored summary read	N01 · Evidence conditionWhich independent postoperative-nausea question is covered?Required	The original question concerns ASA I–II adult women having major gynecologic laparotomy under general anesthesia, with 1 g of powder given once 1 h before surgery and nausea incidence assessed over 24 h. The selected endpoint is the proportion reporting any nausea. R01 R02	The formulation, population, comparison, endpoint and time are identifiable in the retained original.	ASA I–II adult women; major gynecologic laparotomy/general anesthesia; 1 g given 1 h before surgery; placebo comparison of any nausea within 24 h	Material needed: Original reports, plans and linked documents for ASA I–II adult women; major gynecologic laparotomy/general anesthesia; 1 g given 1 h before surgery; placebo comparison of any nausea within 24 h. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
2	Partly verified	Full text not readStored summary read	N02 · Evidence conditionDo the direct and synthesis reports count the same trials more than once?Required	The structured record contains the direct Nanthakomon 2006 report and the Chen 2022 review. The direct 120 participants and the review's 14 RCTs/1506 participants are not added together; unique trial and participant totals remain unverified. R01 R02	Report identities are retained, but review inclusion, overlap and trial-family/team relationships remain unresolved.	The 2006 gynecologic-surgery report, the Chen 2022 review's inclusion table and trial identifiers	Material needed: Original reports, plans and linked documents for The 2006 gynecologic-surgery report, the Chen 2022 review's inclusion table and trial identifiers. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
3	Met	Full text not readStored summary read	N03 · Evidence conditionAre actual reading and the existence of external material distinguished?Required	The full retained record and report/bibliographic summaries were read. External PubMed pages/abstracts, full texts, registration, protocols and SAPs were not opened. R01 R02	Actual summary reading and unread external material are separated.	Reading/acquisition histories for the retained record, PubMed bibliography/abstract, full text, registration, protocol and SAP	Material needed: Original reports, plans and linked documents for Reading/acquisition histories for the retained record, PubMed bibliography/abstract, full text, registration, protocol and SAP. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
4	Partly verified	Full text not readStored summary read	N04 · Evidence conditionWhat surgery, anesthesia and adult-women population is covered?Required	The original population is ASA I–II adult women having elective major gynecologic laparotomy under general anesthesia. Detailed eligibility/exclusion, baseline PONV risk and the anesthesia regimen are not provided in the summary. R01 R02	Population, surgery and anesthesia names are retained; actual eligibility and baseline conditions need further material.	Eligibility/exclusion for ASA I–II adult women undergoing elective major gynecologic laparotomy under general anesthesia	Material needed: Original reports, plans and linked documents for Eligibility/exclusion for ASA I–II adult women undergoing elective major gynecologic laparotomy under general anesthesia. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
5	Partly verified	Full text not readStored summary read	N05 · Evidence conditionWhat dried ginger-powder formulation and product specifications are recorded?Required	The formulation is 2 capsules of 500 mg dried ginger powder; the retained funding description names Khao-la-o Laboratories powder. Quantification/manufacturing specifications and the supply role lack detail. R01	Product/formulation identity is distinguished from standardization and support facts.	Rhizome, 2 capsules of 500 mg, Khao-la-o powder and ingredient quantification	Material needed: Original reports, plans and linked documents for Rhizome, 2 capsules of 500 mg, Khao-la-o powder and ingredient quantification. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
6	Partly verified	Full text not readStored summary read	N06 · Evidence conditionAre a single 1 g dose 1 hour before surgery and follow-up distinguished?Required	The original regimen is a single oral 1 g dose (2 capsules of 500 mg) given 1 hour before surgery, with 24 h follow-up. Actual ingestion, adherence and timing deviations are not established in the summary. R01	Nominal administration and follow-up are recorded; actual implementation remains unverified.	One 1 g dose (2 capsules of 500 mg), given 1 h before surgery; 24 h follow-up; actual administration/adherence	Material needed: Original reports, plans and linked documents for One 1 g dose (2 capsules of 500 mg), given 1 h before surgery; 24 h follow-up; actual administration/adherence. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
7	Partly verified	Full text not readStored summary read	N07 · Evidence conditionWhat placebo and common anesthesia/rescue treatment are described?Required	The comparison specifies appearance- and odor-matched lactose placebo and the same anesthesia/rescue care. Drugs, doses, actual use and arm-specific handling lack detail in the current summary. R01	A placebo/common-care statement is distinct from verifying actual concomitant treatment methods.	Actual contents of appearance- and odor-matched lactose placebo and the same anesthesia/rescue care	Material needed: Original reports, plans and linked documents for Actual contents of appearance- and odor-matched lactose placebo and the same anesthesia/rescue care. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
8	Partly verified	Full text not readStored summary read	N08 · Evidence conditionWhat outcome is nausea incidence within 24 hours?Required	The selected endpoint is the proportion reporting any nausea within 24 h. The direct summary assigns 29/60 versus 40/60 and P=.042 to this outcome. R01	The incidence contract and reported values are retained; collection/definition and prespecification details remain unresolved.	Definition and collection of the proportion reporting any nausea within 24 h	Material needed: Original reports, plans and linked documents for Definition and collection of the proportion reporting any nausea within 24 h. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
9	Partly verified	Full text not readStored summary read	N09 · Evidence conditionAre scores/severity at 2, 6 and 12 hours the same outcome?Required boundary	The review reports a positive direction in nausea scores at 2, 6 and 12 h, while the Korean narrative describes reduced nausea severity. These measures/time points differ from the proportion affected within 24 h. R02	Time-specific score directions are retained; scales, denominators and trial-specific original results remain unverified.	Definitions, denominators and scales for the review's nausea scores/severity at 2/6/12 h	Material needed: Original reports, plans and linked documents for Definitions, denominators and scales for the review's nausea scores/severity at 2/6/12 h. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
10	Partly verified	Full text not readStored summary read	N10 · Evidence conditionAre vomiting, composite PONV and rescue-medication outcomes separated?Required boundary	The review summary reports null incidence results for vomiting, composite PONV and rescue medication; the Korean narrative describes these as mostly null. They remain separate endpoints from nausea incidence within 24 h. R02	Unfavorable/no-difference directions for other endpoints are retained; endpoint-specific estimates and times remain unverified.	Definitions, times and denominators for each outcome, and the review's null-result statements	Material needed: Original reports, plans and linked documents for Definitions, times and denominators for each outcome, and the review's null-result statements. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
11	Partly verified	Full text not readStored summary read	N11 · Evidence conditionWhat denominators do 120 participants, 60/60 and 29/60 versus 40/60 represent?Required	The original sample is 120 participants, 60/60, with nausea within 24 h in 29/60 versus 40/60. Detailed flow is needed to establish whether allocated, completed, measured and analyzed denominators coincide. R01	Only stored event counts/denominators are retained; further participant counts or denominator meanings are not established.	Allocated/completed/analyzed participants and patients experiencing nausea within 24 h	Material needed: Original reports, plans and linked documents for Allocated/completed/analyzed participants and patients experiencing nausea within 24 h. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
12	Unverified	Full text not readStored summary read	N12 · Evidence conditionAre missing data, withdrawals and analysis handling verified?Required	The current summary does not specify arm-specific withdrawals, follow-up loss, missing-data handling, analysis populations or sensitivity analyses within 24 h. R01	The 60/60 notation and generic English participant wording cannot establish complete follow-up or analysis handling.	Arm-specific observation loss within 24 h, withdrawal reasons, analysis populations and handling	Material needed: Original reports, plans and linked documents for Arm-specific observation loss within 24 h, withdrawal reasons, analysis populations and handling. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
13	Partly verified	Full text not readStored summary read	N13 · Evidence conditionIs the stored RR of about 0.725 an original-paper estimate?Required	The original evidence and bibliography record 29/60 versus 40/60, P=.042 and a calculated RR of about 0.725, with the original 95% CI unverified. This RR is a retained historical calculation, not a new calculation in this work. R01	Reported events, P and the provenance level of the existing calculation are distinguished; the original reported interval remains unresolved.	29/60 versus 40/60, P=.042 and the calculated-RR label in the original evidence/bibliography	Material needed: Original reports, plans and linked documents for 29/60 versus 40/60, P=.042 and the calculated-RR label in the original evidence/bibliography. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
14	Partly verified	Full text not readStored summary read	N14 · Evidence conditionHow are other surgery and cesarean-delivery findings retained?Required boundary	The Korean/English narratives describe very low certainty and an unestablished nausea benefit in a cesarean-only Cochrane analysis. The structured bibliography contains no separate Cochrane citation or inclusion table. R01 R02	Opposing/uncertain background is retained without counting it as direct replication under the same surgery/anesthesia.	Other surgery/anesthesia, cesarean-only Cochrane statements and differences from the direct question	Material needed: Original reports, plans and linked documents for Other surgery/anesthesia, cesarean-only Cochrane statements and differences from the direct question. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
15	Met	Full text not readStored summary read	N15 · Evidence conditionWhat do the Korean 2021 narrative, Chen 2022 citation and dates mean?Required	The original verdict date 2026-09-08, correction date 2026-09-14 and Korean/English narrative about two 2021 meta-analyses are retained. The explicit citation is Chen 2022; no collection year was inferred. New clinical searches in this work: 0. R01 R02	Narrative year, citation year, original verdict date and current review are distinguished.	The Korean/English narrative about two 2021 meta-analyses, the explicit Chen 2022 citation and original verdict/correction dates	Material needed: Original reports, plans and linked documents for The Korean/English narrative about two 2021 meta-analyses, the explicit Chen 2022 citation and original verdict/correction dates. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
16	Unverified	Full text not readStored summary read	N16 · Evidence conditionHow far are research funding sources verified?Supplementary; required for independent-funding claims	The direct funding description says the funding source is unverified; the review describes mixed original-trial funding. The Khao-la-o brand or historical I1 axis is not an original declaration of independent funding. R01 R02	Specific sources/company roles remain unverified beyond report-specific funding statements.	The direct trial's funding/company role and funding of original trials in the review	Material needed: Original reports, plans and linked documents for The direct trial's funding/company role and funding of original trials in the review. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
17	Unverified	Full text not readStored summary read	N17 · Evidence conditionAre product supply and support verified?Supplementary; required for support-independence claims	The original funding description names Khao-la-o Laboratories powder but does not specify actual supply/free-support scope or roles. R01	A product name is distinguished from verification of provision/support.	Declarations about Khao-la-o powder supply, free provision and roles	Material needed: Original reports, plans and linked documents for Declarations about Khao-la-o powder supply, free provision and roles. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
18	Unverified	Full text not readStored summary read	N18 · Evidence conditionAre employee authorship and research teams verified?Supplementary; required for team-independence claims	The retained summary contains no concrete finding on company employment, affiliations or author contributions. The English funding description only contains generic wording about separate assessment of employee authorship and related matters. R01 R02	There is no original record verifying employee-authorship presence/absence or independent-team relationships.	Author affiliations, company employment and team/report-family relationships	Material needed: Original reports, plans and linked documents for Author affiliations, company employment and team/report-family relationships. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
19	Unverified	Full text not readStored summary read	N19 · Evidence conditionHow far are declared conflicts and patents verified?Supplementary; required for conflict-of-interest claims	The current retained record lacks detailed original conflict-of-interest/patent declarations. Generic English funding wording and I1 are retained without treating them as declaration documents. R01 R02	Presence or absence of conflicts cannot be established without comparing original declarations and their scope.	Author/institution declarations of interests, patents and product roles	Material needed: Original reports, plans and linked documents for Author/institution declarations of interests, patents and product roles. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
20	Partly verified	Full text not readStored summary read	N20 · Evidence conditionWhat randomization, concealment and blinding were actually used?Required	The direct study is described as randomized, double-blind and placebo-controlled, with appearance- and odor-matched lactose placebo. Sequence generation, concealment, actual assessor blinding and baseline-risk details are absent. R01	The design label/placebo features are retained; actual allocation/blinding methods still need comparison.	Sequence generation, concealment, assessors and baseline differences in the double-blind placebo trial	Material needed: Original reports, plans and linked documents for Sequence generation, concealment, assessors and baseline differences in the double-blind placebo trial. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
21	Partly verified	Full text not readStored summary read	N21 · Evidence conditionCould anesthesia, prophylaxis or rescue-care differences obscure the intervention's contribution?Required	The original comparison states the same anesthesia/rescue care. Actual administration, arm-specific use and handling of anesthetics, prophylactic antiemetics and rescue medication lack detail. R01 R02	A common-care statement is separate from differences/deviations in actual concurrent interventions.	Arm-specific anesthetics, prophylactic antiemetics, rescue care, adherence/deviations and handling	Material needed: Original reports, plans and linked documents for Arm-specific anesthetics, prophylactic antiemetics, rescue care, adherence/deviations and handling. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
22	Partly verified	Full text not readStored summary read	N22 · Evidence conditionWho collected nausea, when and with which scale?Required	The current scope specifies the proportion reporting any nausea within 24 h. The summary lacks detail on who assessed it, when, which question/scale was used and assessor blinding/recall. R01 R02	The incidence definition is retained; actual measurement procedures and missingness remain unresolved.	Questions, assessor blinding, visits, recall and severity measurement for any nausea within 24 h	Material needed: Original reports, plans and linked documents for Questions, assessor blinding, visits, recall and severity measurement for any nausea within 24 h. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
23	Unverified	Full text not readStored summary read	N23 · Evidence conditionWhich intervention effect does the 24 h analysis estimate?Required	Event comparisons are reported, but assignment/adherence effects, ITT/PP, adjustment and actual analysis populations/models are not specified in the retained summary. R01	An event denominator of 60 cannot establish the analysis plan or effect of interest.	Assignment/adherence effects, ITT/PP, adjustment and analysis populations/models	Material needed: Original reports, plans and linked documents for Assignment/adherence effects, ITT/PP, adjustment and analysis populations/models. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
24	Unverified	Full text not readStored summary read	N24 · Evidence conditionWas nausea alone a prespecified primary (1st) endpoint?Required	The original reader answer says prespecified primary (1st) status for nausea alone is unverified; trial registration is recorded as unverified. R01	The current nausea outcome within 24 h is distinguished from a preregistered hierarchy; comparison material remains needed.	Endpoints, times and multiplicity in direct-trial registration, protocol and SAP	Material needed: Original reports, plans and linked documents for Endpoints, times and multiplicity in direct-trial registration, protocol and SAP. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
25	Unverified	Full text not readStored summary read	N25 · Evidence conditionAre the original between-group 95% CI and precision verified?Required	The original result records P=.042 and an existing calculated RR of about 0.725; the original 95% CI remains unverified. R01	Without the original reported interval, precision and the range of compatible effect sizes cannot be established.	The reported direct effect, 95% CI, variance and denominator for nausea within 24 h	Material needed: Original reports, plans and linked documents for The reported direct effect, 95% CI, variance and denominator for nausea within 24 h. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
26	Unverified	Full text not readStored summary read	N26 · Evidence conditionWhat defines clinical importance of the incidence difference?Required	The current retained record has no justified clinical-importance threshold or original interval for a difference in nausea incidence within 24 h in this surgery/anesthesia and population. R01	Material to compare the reported interval with clinical-importance evidence remains unverified.	Clinical-importance criteria and reported intervals for the relevant surgery/anesthesia and population	Material needed: Original reports, plans and linked documents for Clinical-importance criteria and reported intervals for the relevant surgery/anesthesia and population. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
27	Unverified	Full text not readStored summary read	N27 · Evidence conditionIs there independent replication for the same surgery, anesthesia, formulation and nausea outcome within 24 h?Required	The original narrative leaves same-condition independent replication unverified. The review's 14 RCTs do not establish 14 replications with the same surgery/anesthesia, endpoint and time. R01 R02	Trial-specific conditions, registration/families and team identities are not retained.	Original-trial families, research teams and trial-specific results matching the conditions	Material needed: Original reports, plans and linked documents for Original-trial families, research teams and trial-specific results matching the conditions. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
28	Unverified	Full text not readStored summary read	N28 · Evidence conditionDoes the evidence establish other doses, repeated dosing or optimal timing?Supplementary; required for optimal-condition claims	The current direct question is a single 1 g powder dose given 1 h before surgery. The retained summary contains no direct superiority comparison of doses, timings or repeated regimens of the same formulation. R01	The selected regimen is separated from extension claims about optimal conditions.	Direct dose/timing and repeated-regimen comparisons using the same powder formulation	Material needed: Original reports, plans and linked documents for Direct dose/timing and repeated-regimen comparisons using the same powder formulation. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
29	Partly verified	Full text not readStored summary read	N29 · Evidence conditionDoes the evidence answer outcomes beyond 24 h or in other populations?Supplementary; required for persistence/extensions	Follow-up is 24 h, and the original narrative rejects equal benefit in every surgery. Delayed nausea, long-term outcomes and special-population follow-up are unverified in the summary. R01	The acute time window is distinguished from gaps in extension questions.	Delayed nausea after cessation, long-term outcomes, special populations and other anesthesia	Material needed: Original reports, plans and linked documents for Delayed nausea after cessation, long-term outcomes, special populations and other anesthesia. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
30	Met	Full text not readStored summary read	N30 · Evidence conditionDoes a nausea result establish vomiting/aspiration prevention or replacement of prophylaxis?Supplementary; required for extension claims	The original scope note assesses nausea incidence within 24 h and separates vomiting/composite PONV. The advertising limits exclude prophylactic-antiemetic replacement, vomiting/aspiration prevention and equal effects in every surgery. R01 R02	The boundary between the selected symptom and separate event/drug-replacement questions is explicitly retained.	Direct outcomes for nausea incidence, vomiting, aspiration and prophylaxis replacement	Material needed: Original reports, plans and linked documents for Direct outcomes for nausea incidence, vomiting, aspiration and prophylaxis replacement. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
31	Unverified	Full text not readStored summary read	N31 · Evidence conditionWhich harms were collected in the direct trial?Supplementary; required for safety claims	The current retained record provides preoperative caution wording and nausea-prevention results but no detailed table of ginger-attributed adverse-event definitions, collection or discontinuation. R01	Reduced nausea is different evidence from harm collection or a complete safety tally.	Adverse-event definitions, collection and discontinuation around surgery after a single 1 g powder dose	Material needed: Original reports, plans and linked documents for Adverse-event definitions, collection and discontinuation around surgery after a single 1 g powder dose. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
32	Partly verified	Full text not readStored summary read	N32 · Evidence conditionWhat level of information is the fasting/aspiration caution?Supplementary	The original safety advice prioritizes the anesthesia/surgical team's judgment about fasting/aspiration risk and says not to self-administer. Actual aspiration events and incidence denominators are absent from the summary. R01	The caution is retained separately from risk incidence or aspiration-prevention efficacy.	Original fasting/aspiration caution, actual administration, aspiration events and anesthesia-team decisions	Material needed: Original reports, plans and linked documents for Original fasting/aspiration caution, actual administration, aspiration events and anesthesia-team decisions. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
33	Partly verified	Full text not readStored summary read	N33 · Evidence conditionAre harms with anticoagulant/antiplatelet use verified?Supplementary; required for the specified harm claim	The original advice prioritizes the surgical team's judgment for anticoagulant/antiplatelet use. Actual bleeding/interactions and concomitant-use denominators are unverified in the retained summary. R01	Advice is different from verified effects or incidence of harms during concomitant use.	Concomitant drugs, baseline risk, bleeding/interactions and exposure data	Material needed: Original reports, plans and linked documents for Concomitant drugs, baseline risk, bleeding/interactions and exposure data. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
34	Unverified	Full text not readStored summary read	N34 · Evidence conditionAre harm denominators and observation losses verified?Supplementary; required for incidence claims	Beyond the nausea event denominators of 29/60 versus 40/60, the current summary provides no overall harm, bleeding or aspiration events/exposure time or collection losses. R01	An efficacy-endpoint denominator does not replace an incidence denominator for a separate harm.	Arm-specific people/events with harms, exposure time, collection, missingness and discontinuation	Material needed: Original reports, plans and linked documents for Arm-specific people/events with harms, exposure time, collection, missingness and discontinuation. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
35	Met	Full text not readStored summary read	N35 · Evidence conditionAre efficacy comparisons distinguished from harm signals and causation?Required boundary	The current comparison concerns nausea-prevention efficacy against placebo. Original C46, caution, the historical I1/axes and cross-check wording are retained without converting them into ginger-caused nausea or a new safety judgment. R01 R02	The direction of efficacy versus harm signals/causation and current interpretation limits are distinguished.	The placebo comparison of nausea within 24 h and separate harm, timing, alternative-cause and safety scopes	Material needed: Original reports, plans and linked documents for The placebo comparison of nausea within 24 h and separate harm, timing, alternative-cause and safety scopes. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
36	Partly verified	Full text not readStored summary read	N36 · Evidence conditionAre review PROSPERO registration and direct-trial registration distinguished?Required	Direct-trial registration is unverified. PROSPERO CRD42020220916 in the Chen review citation is retained as review registration and is not used as preregistration of the original 2006 trial. R01 R02	Review/direct-trial identity levels are distinguished; actual registration/plan comparison remains unresolved.	Unverified direct-trial registration, Chen review CRD42020220916 and linked plans	Material needed: Original reports, plans and linked documents for Unverified direct-trial registration, Chen review CRD42020220916 and linked plans. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
37	Met	Full text not readStored summary read	N37 · Evidence conditionWhat information do generic English evidence-table wording, past corrections and the two languages provide?Required boundary	Generic participant/funding/endpoint/result/weight wording remains in the current English evidence table; the correction reports replacement of 2 fields. The Korean/English text and correction statement are preserved in the original. R01 R02	Generic wording is distinguished from the actual original summary without using it as new denominator/company/result verification.	Generic original English participant/funding/endpoint/result/weight wording and the correction statement dated 2026-09-14	Material needed: Original reports, plans and linked documents for Generic original English participant/funding/endpoint/result/weight wording and the correction statement dated 2026-09-14. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.

No items match your search or filter.

37 itemsWhat the statuses mean

Assessment scope

Stored-material review date: 2026-10-06
Original evidence cut-off: 2026-09-08
Scope actually checked: Retained Korean/English summaries and case-specific conditions/application records. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: The material-review record dated 2026-10-06 concerns the retained summary. The separate condition 1.1 reapplication that day is not external full-text reading. The original verdict date 2026-09-08 and correction date 2026-09-14 are not changed into new-search or full-text-reading dates.
Population: ASA I–II adult women undergoing elective major gynecologic laparotomy under general anesthesia. Detailed eligibility and baseline nausea risk remain unverified.
Ingredient, formulation and route: Oral dried ginger powder from Zingiber officinale Roscoe rhizome. The Khao-la-o Laboratories product name is distinguished from verified supply, support or funding.
Dose: 2 capsules of 500 mg; a single 1 g dose 1 hour before surgery. Actual ingestion, adherence and timing deviations remain unverified.
Comparator: Appearance- and odor-matched lactose placebo with the same anesthesia and rescue care. Actual drugs, doses, arm-specific use and handling remain unverified.
Measured outcome: The proportion reporting any nausea within 24 postoperative hours. This is distinct from nausea episodes, scores, severity, vomiting and composite PONV.
Duration: A single preoperative administration with 24 hours of postoperative follow-up. Delayed nausea, long-term results and other populations are separate questions.
Questions outside this scope: Null statements about vomiting/composite PONV are not changed into an effect of 0 or equivalence for nausea incidence.; Nausea scores at 2, 6 and 12 hours differ in time and measure from the proportion affected within 24 hours.; Rescue-medication results are distinguished from claims of replacing prophylactic antiemetics.; Results from cesarean delivery or other surgery/anesthesia are not counted as independent same-condition replications.; Nausea prevention is not expanded into aspiration prevention, long-term safety or individual preoperative dosing advice.; The single 1 g dried-powder question is not converted into superiority claims about other formulations, doses or repeated regimens.

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

R01 · Nanthakomon·Pongrojpaw (2006): The efficacy of ginger in prevention of postoperative nausea and vomiting after major gynecologic surgery

PubMed

Material type: Randomized double-blind placebo-controlled trial
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Findings recorded in the stored summary: 29/60 versus 40/60, P=.042; a retained calculated RR of about 0.725, with the original 95% CI unverified
Record level: Reported values and limitations from the retained summary; not results of new external reading or calculations.
Study overlap and independent replication: The 120 participants/60/60 in the 2006 direct report and the 14 RCTs/1506 participants in the 2022 review are not added together. Included trials, overlap, independent teams under the same conditions and unique participant counts remain unverified.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained research/bibliographic summary	Retained existing summary acquired	Current retained local input acquired	True	The full retained record was read and this report's summary/bibliography was identified at exact locations. Nanthakomon T, Pongrojpaw D. J Med Assoc Thai. 2006;89 Suppl 4:S130-S136. PMID: 17725149. The direct trial's original interval, prespecified endpoints, funding, supply and independent replication remain unverified. A product name is not verification of actual support. The material-review record dated 2026-10-06 concerns the retained summary. The separate condition 1.1 reapplication that day is not external full-text reading. The original verdict date 2026-09-08 and correction date 2026-09-14 are not changed into new-search or full-text-reading dates.
External article abstract	External material; existence/public availability/acquisition separately unverified	Access not attempted; unread	False	The stored URL exists; actual external bibliography/abstract readings in this work: 0. The direct trial's original interval, prespecified endpoints, funding, supply and independent replication remain unverified. A product name is not verification of actual support. The material-review record dated 2026-10-06 concerns the retained summary. The separate condition 1.1 reapplication that day is not external full-text reading. The original verdict date 2026-09-08 and correction date 2026-09-14 are not changed into new-search or full-text-reading dates.
External article full text	External material; existence/public availability/acquisition separately unverified	Full text not acquired; unread	False	A DOI, where present, serves only as a retained identifier/link and does not establish full-text reading. The direct trial's original interval, prespecified endpoints, funding, supply and independent replication remain unverified. A product name is not verification of actual support. The material-review record dated 2026-10-06 concerns the retained summary. The separate condition 1.1 reapplication that day is not external full-text reading. The original verdict date 2026-09-08 and correction date 2026-09-14 are not changed into new-search or full-text-reading dates.
Direct-trial registration original	External material; existence/public availability/acquisition separately unverified	Original registration unread	False	Review PROSPERO identity is separated from unverified original-trial registration; neither nonregistration nor prespecified endpoints are established. The direct trial's original interval, prespecified endpoints, funding, supply and independent replication remain unverified. A product name is not verification of actual support. The material-review record dated 2026-10-06 concerns the retained summary. The separate condition 1.1 reapplication that day is not external full-text reading. The original verdict date 2026-09-08 and correction date 2026-09-14 are not changed into new-search or full-text-reading dates.
Protocol material needed (existence unverified)	External material; existence/public availability/acquisition separately unverified	Existence/public availability/acquisition unverified; unread	False	The absence of a current link/original does not establish no protocol or selective reporting. The direct trial's original interval, prespecified endpoints, funding, supply and independent replication remain unverified. A product name is not verification of actual support. The material-review record dated 2026-10-06 concerns the retained summary. The separate condition 1.1 reapplication that day is not external full-text reading. The original verdict date 2026-09-08 and correction date 2026-09-14 are not changed into new-search or full-text-reading dates.
Statistical-analysis-plan material needed (existence unverified)	External material; existence/public availability/acquisition separately unverified	Existence/public availability/acquisition unverified; unread	False	No current analysis-plan comparison was performed; ITT/PP/prespecified hierarchy are not inferred. The direct trial's original interval, prespecified endpoints, funding, supply and independent replication remain unverified. A product name is not verification of actual support. The material-review record dated 2026-10-06 concerns the retained summary. The separate condition 1.1 reapplication that day is not external full-text reading. The original verdict date 2026-09-08 and correction date 2026-09-14 are not changed into new-search or full-text-reading dates.
Product specification/supply/support material needed	External material; existence/public availability/acquisition separately unverified	Existence/public availability/acquisition unverified; unread	False	Product identity/dose remain at the original-record level; separate original documents are needed for quantification/company supply. The direct trial's original interval, prespecified endpoints, funding, supply and independent replication remain unverified. A product name is not verification of actual support. The material-review record dated 2026-10-06 concerns the retained summary. The separate condition 1.1 reapplication that day is not external full-text reading. The original verdict date 2026-09-08 and correction date 2026-09-14 are not changed into new-search or full-text-reading dates.
Funding/employee-authorship/conflict material needed	External material; existence/public availability/acquisition separately unverified	Existence/public availability/acquisition unverified; unread	False	Funding, support, employee authorship and declared conflicts are separately unverified; generic English wording/historical axes do not upgrade them. The direct trial's original interval, prespecified endpoints, funding, supply and independent replication remain unverified. A product name is not verification of actual support. The material-review record dated 2026-10-06 concerns the retained summary. The separate condition 1.1 reapplication that day is not external full-text reading. The original verdict date 2026-09-08 and correction date 2026-09-14 are not changed into new-search or full-text-reading dates.

R02 · Chen and colleagues (2022): The preventive and relieving effects of ginger on postoperative nausea and vomiting: A systematic review and meta-analysis of randomized controlled trials

PubMed

Material type: Systematic review and meta-analysis of RCTs
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Findings recorded in the stored summary: Positive nausea-score direction at 2, 6 and 12 hours; null incidence findings for vomiting, composite PONV and rescue medication
Record level: Reported values and limitations from the retained summary; not results of new external reading or calculations.
Study overlap and independent replication: The 120 participants/60/60 in the 2006 direct report and the 14 RCTs/1506 participants in the 2022 review are not added together. Included trials, overlap, independent teams under the same conditions and unique participant counts remain unverified.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained research/bibliographic summary	Retained existing summary acquired	Current retained local input acquired	True	The full retained record was read and this report's summary/bibliography was identified at exact locations. Chen CC et al. Complement Ther Med. 2022;64:102812. PMID: 34700257. DOI: 10.1016/j.ctim.2021.102812. PROSPERO CRD42020220916. CRD42020220916 is a bibliographic review-registration identifier; it does not establish preregistration of the 2006 original trial or current reading of registration contents. The material-review record dated 2026-10-06 concerns the retained summary. The separate condition 1.1 reapplication that day is not external full-text reading. The original verdict date 2026-09-08 and correction date 2026-09-14 are not changed into new-search or full-text-reading dates.
External article abstract	External material; existence/public availability/acquisition separately unverified	Access not attempted; unread	False	The stored URL exists; actual external bibliography/abstract readings in this work: 0. CRD42020220916 is a bibliographic review-registration identifier; it does not establish preregistration of the 2006 original trial or current reading of registration contents. The material-review record dated 2026-10-06 concerns the retained summary. The separate condition 1.1 reapplication that day is not external full-text reading. The original verdict date 2026-09-08 and correction date 2026-09-14 are not changed into new-search or full-text-reading dates.
External article full text	External material; existence/public availability/acquisition separately unverified	Full text not acquired; unread	False	A DOI, where present, serves only as a retained identifier/link and does not establish full-text reading. CRD42020220916 is a bibliographic review-registration identifier; it does not establish preregistration of the 2006 original trial or current reading of registration contents. The material-review record dated 2026-10-06 concerns the retained summary. The separate condition 1.1 reapplication that day is not external full-text reading. The original verdict date 2026-09-08 and correction date 2026-09-14 are not changed into new-search or full-text-reading dates.
Review-registration original	External material; existence/public availability/acquisition separately unverified	Original registration unread	False	Review PROSPERO identity is separated from unverified original-trial registration; neither nonregistration nor prespecified endpoints are established. CRD42020220916 is a bibliographic review-registration identifier; it does not establish preregistration of the 2006 original trial or current reading of registration contents. The material-review record dated 2026-10-06 concerns the retained summary. The separate condition 1.1 reapplication that day is not external full-text reading. The original verdict date 2026-09-08 and correction date 2026-09-14 are not changed into new-search or full-text-reading dates.
Protocol material needed (existence unverified)	External material; existence/public availability/acquisition separately unverified	Existence/public availability/acquisition unverified; unread	False	The absence of a current link/original does not establish no protocol or selective reporting. CRD42020220916 is a bibliographic review-registration identifier; it does not establish preregistration of the 2006 original trial or current reading of registration contents. The material-review record dated 2026-10-06 concerns the retained summary. The separate condition 1.1 reapplication that day is not external full-text reading. The original verdict date 2026-09-08 and correction date 2026-09-14 are not changed into new-search or full-text-reading dates.
Statistical-analysis-plan material needed (existence unverified)	External material; existence/public availability/acquisition separately unverified	Existence/public availability/acquisition unverified; unread	False	No current analysis-plan comparison was performed; ITT/PP/prespecified hierarchy are not inferred. CRD42020220916 is a bibliographic review-registration identifier; it does not establish preregistration of the 2006 original trial or current reading of registration contents. The material-review record dated 2026-10-06 concerns the retained summary. The separate condition 1.1 reapplication that day is not external full-text reading. The original verdict date 2026-09-08 and correction date 2026-09-14 are not changed into new-search or full-text-reading dates.

Report counts versus independent study counts

The 120 participants/60/60 in the 2006 direct report and the 14 RCTs/1506 participants in the 2022 review are not added together. Included trials, overlap, independent teams under the same conditions and unique participant counts remain unverified.

Review criteria

Version 1.1 · Criteria record date 2026-10-06. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · Which independent postoperative-nausea question is covered?

Required materials and conditions: ASA I–II adult women; major gynecologic laparotomy/general anesthesia; 1 g given 1 h before surgery; placebo comparison of any nausea within 24 h
Conditions for verification: Link the original question to the proportion reporting any nausea within 24 h.
Requirement and applicability: Required
Application exceptions: Do not combine nausea severity, vomiting, composite PONV or rescue medication into an independent primary effect.
Why this condition is needed: Link the original question to the proportion reporting any nausea within 24 h. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N02 · Do the direct and synthesis reports count the same trials more than once?

Required materials and conditions: The 2006 gynecologic-surgery report, the Chen 2022 review's inclusion table and trial identifiers
Conditions for verification: Distinguish report/trial families for the direct 120 participants and the review's 14 RCTs/1506 participants without adding them together.
Requirement and applicability: Required
Application exceptions: Do not count a review, its original trials or repeated endpoint/time-point citations as independent replication.
Why this condition is needed: Distinguish report/trial families for the direct 120 participants and the review's 14 RCTs/1506 participants without adding them together. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N03 · Are actual reading and the existence of external material distinguished?

Required materials and conditions: Reading/acquisition histories for the retained record, PubMed bibliography/abstract, full text, registration, protocol and SAP
Conditions for verification: Display current reading of the stored summary separately from unread external material.
Requirement and applicability: Required
Application exceptions: A URL or the original verdict date does not establish full-text reading in this work.
Why this condition is needed: Display current reading of the stored summary separately from unread external material. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N04 · What surgery, anesthesia and adult-women population is covered?

Required materials and conditions: Eligibility/exclusion for ASA I–II adult women undergoing elective major gynecologic laparotomy under general anesthesia
Conditions for verification: Distinguish the direct population from cesarean delivery, other surgery/anesthesia, other sexes and baseline conditions.
Requirement and applicability: Required
Application exceptions: A shared postoperative-nausea label does not justify transfer to every population.
Why this condition is needed: Distinguish the direct population from cesarean delivery, other surgery/anesthesia, other sexes and baseline conditions. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N05 · What dried ginger-powder formulation and product specifications are recorded?

Required materials and conditions: Rhizome, 2 capsules of 500 mg, Khao-la-o powder and ingredient quantification
Conditions for verification: Distinguish the dried-powder formulation and brand wording from verification of standardization/product support.
Requirement and applicability: Required
Application exceptions: Do not turn a product name into evidence of an extract, company funding or free supply.
Why this condition is needed: Distinguish the dried-powder formulation and brand wording from verification of standardization/product support. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N06 · Are a single 1 g dose 1 hour before surgery and follow-up distinguished?

Required materials and conditions: One 1 g dose (2 capsules of 500 mg), given 1 h before surgery; 24 h follow-up; actual administration/adherence
Conditions for verification: Record dose, timing and frequency separately from postoperative observation duration.
Requirement and applicability: Required
Application exceptions: Do not fill other doses or repeated regimens with the same effect estimate.
Why this condition is needed: Record dose, timing and frequency separately from postoperative observation duration. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N07 · What placebo and common anesthesia/rescue treatment are described?

Required materials and conditions: Actual contents of appearance- and odor-matched lactose placebo and the same anesthesia/rescue care
Conditions for verification: Distinguish planned common care from actual drugs, administration, rescue-treatment differences and handling.
Requirement and applicability: Required
Application exceptions: Matching appearance/odor does not verify every blinding procedure or every concomitant treatment.
Why this condition is needed: Distinguish planned common care from actual drugs, administration, rescue-treatment differences and handling. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N08 · What outcome is nausea incidence within 24 hours?

Required materials and conditions: Definition and collection of the proportion reporting any nausea within 24 h
Conditions for verification: Distinguish events/denominators for a patient proportion from nausea episodes, scores and vomiting.
Requirement and applicability: Required
Application exceptions: The page's selected endpoint does not establish that it was a preregistered primary (1st) endpoint.
Why this condition is needed: Distinguish events/denominators for a patient proportion from nausea episodes, scores and vomiting. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N09 · Are scores/severity at 2, 6 and 12 hours the same outcome?

Required materials and conditions: Definitions, denominators and scales for the review's nausea scores/severity at 2/6/12 h
Conditions for verification: Attribute positive time-specific score directions to a measure distinct from the proportion affected within 24 h.
Requirement and applicability: Required boundary
Application exceptions: Do not turn scores into 24 h event counts or effects from the direct original trial.
Why this condition is needed: Attribute positive time-specific score directions to a measure distinct from the proportion affected within 24 h. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N10 · Are vomiting, composite PONV and rescue-medication outcomes separated?

Required materials and conditions: Definitions, times and denominators for each outcome, and the review's null-result statements
Conditions for verification: Retain nausea-benefit statements alongside null statements for other endpoints.
Requirement and applicability: Required boundary
Application exceptions: Do not replace null/nonsignificant findings with an effect of 0, equivalence or absence of a nausea result within 24 h.
Why this condition is needed: Retain nausea-benefit statements alongside null statements for other endpoints. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N11 · What denominators do 120 participants, 60/60 and 29/60 versus 40/60 represent?

Required materials and conditions: Allocated/completed/analyzed participants and patients experiencing nausea within 24 h
Conditions for verification: Retain the original 120 participants, 60/60 and 29/60 versus 40/60 at the reported level.
Requirement and applicability: Required
Application exceptions: Do not assume all allocated, completed, measured and analyzed denominators are identical.
Why this condition is needed: Retain the original 120 participants, 60/60 and 29/60 versus 40/60 at the reported level. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N12 · Are missing data, withdrawals and analysis handling verified?

Required materials and conditions: Arm-specific observation loss within 24 h, withdrawal reasons, analysis populations and handling
Conditions for verification: Identify the need to verify actual follow-up/completion and missing-data handling beyond the original event denominators.
Requirement and applicability: Required
Application exceptions: No withdrawal/missing-data information does not establish 0 losses or complete follow-up.
Why this condition is needed: Identify the need to verify actual follow-up/completion and missing-data handling beyond the original event denominators. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N13 · Is the stored RR of about 0.725 an original-paper estimate?

Required materials and conditions: 29/60 versus 40/60, P=.042 and the calculated-RR label in the original evidence/bibliography
Conditions for verification: Label the RR of about 0.725 only as a stored historical calculation and retain the unverified original 95% CI.
Requirement and applicability: Required
Application exceptions: Do not calculate a new RR/RD/NNT/CI or promote the stored value to an original-paper estimate.
Why this condition is needed: Label the RR of about 0.725 only as a stored historical calculation and retain the unverified original 95% CI. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N14 · How are other surgery and cesarean-delivery findings retained?

Required materials and conditions: Other surgery/anesthesia, cesarean-only Cochrane statements and differences from the direct question
Conditions for verification: Keep cesarean-only statements of very low certainty and unestablished nausea benefit in a separate context.
Requirement and applicability: Required boundary
Application exceptions: Do not add other surgeries as independent replications under the same gynecologic laparotomy/general-anesthesia conditions.
Why this condition is needed: Keep cesarean-only statements of very low certainty and unestablished nausea benefit in a separate context. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N15 · What do the Korean 2021 narrative, Chen 2022 citation and dates mean?

Required materials and conditions: The Korean/English narrative about two 2021 meta-analyses, the explicit Chen 2022 citation and original verdict/correction dates
Conditions for verification: Retain narrative years and citation publication years without inferring collection years or additional reports.
Requirement and applicability: Required
Application exceptions: No new search does not mean 0 studies or verification of current publication/retraction status.
Why this condition is needed: Retain narrative years and citation publication years without inferring collection years or additional reports. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N16 · How far are research funding sources verified?

Required materials and conditions: The direct trial's funding/company role and funding of original trials in the review
Conditions for verification: Distinguish the direct trial's unverified funding source from mixed funding statements about the review's original trials.
Requirement and applicability: Supplementary; required for independent-funding claims
Application exceptions: Historical I1 or a product name does not verify independent funding.
Why this condition is needed: Distinguish the direct trial's unverified funding source from mixed funding statements about the review's original trials. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N17 · Are product supply and support verified?

Required materials and conditions: Declarations about Khao-la-o powder supply, free provision and roles
Conditions for verification: Record the product brand separately from actual supply/support scope.
Requirement and applicability: Supplementary; required for support-independence claims
Application exceptions: A named product does not establish free supply or absence of support.
Why this condition is needed: Record the product brand separately from actual supply/support scope. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N18 · Are employee authorship and research teams verified?

Required materials and conditions: Author affiliations, company employment and team/report-family relationships
Conditions for verification: Do not use generic English wording to fill employee-authorship or independent-team presence/absence.
Requirement and applicability: Supplementary; required for team-independence claims
Application exceptions: A review's repeated direction does not establish same-condition replication by a different independent research team.
Why this condition is needed: Do not use generic English wording to fill employee-authorship or independent-team presence/absence. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N19 · How far are declared conflicts and patents verified?

Required materials and conditions: Author/institution declarations of interests, patents and product roles
Conditions for verification: Do not label unread/unverified declarations as no conflicts or no bias.
Requirement and applicability: Supplementary; required for conflict-of-interest claims
Application exceptions: Historical axes, brands and generic English funding wording do not replace declaration documents.
Why this condition is needed: Do not label unread/unverified declarations as no conflicts or no bias. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N20 · What randomization, concealment and blinding were actually used?

Required materials and conditions: Sequence generation, concealment, assessors and baseline differences in the double-blind placebo trial
Conditions for verification: Distinguish the design label from actual method verification and retain unverified limitations.
Requirement and applicability: Required
Application exceptions: Matched placebo appearance/odor does not verify every blinding procedure.
Why this condition is needed: Distinguish the design label from actual method verification and retain unverified limitations. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N21 · Could anesthesia, prophylaxis or rescue-care differences obscure the intervention's contribution?

Required materials and conditions: Arm-specific anesthetics, prophylactic antiemetics, rescue care, adherence/deviations and handling
Conditions for verification: Distinguish a same-anesthesia/rescue-care statement from unverified actual administration and analysis backgrounds.
Requirement and applicability: Required
Application exceptions: Do not transfer rescue endpoints or concomitant-treatment differences into the effect of ginger alone.
Why this condition is needed: Distinguish a same-anesthesia/rescue-care statement from unverified actual administration and analysis backgrounds. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N22 · Who collected nausea, when and with which scale?

Required materials and conditions: Questions, assessor blinding, visits, recall and severity measurement for any nausea within 24 h
Conditions for verification: Attribute patient incidence and score/severity measures to their actual collection methods.
Requirement and applicability: Required
Application exceptions: Do not fill unread details with complete collection, objective measurement or validated scales.
Why this condition is needed: Attribute patient incidence and score/severity measures to their actual collection methods. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N23 · Which intervention effect does the 24 h analysis estimate?

Required materials and conditions: Assignment/adherence effects, ITT/PP, adjustment and analysis populations/models
Conditions for verification: Distinguish reported event comparisons from verification of actual analysis definitions.
Requirement and applicability: Required
Application exceptions: A denominator of 60 does not justify choosing ITT/PP or performing a new analysis.
Why this condition is needed: Distinguish reported event comparisons from verification of actual analysis definitions. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N24 · Was nausea alone a prespecified primary (1st) endpoint?

Required materials and conditions: Endpoints, times and multiplicity in direct-trial registration, protocol and SAP
Conditions for verification: Retain the selected nausea outcome within 24 h alongside unverified prespecified primary (1st) status.
Requirement and applicability: Required
Application exceptions: A reported significant P does not prove a prespecified primary (1st) success.
Why this condition is needed: Retain the selected nausea outcome within 24 h alongside unverified prespecified primary (1st) status. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N25 · Are the original between-group 95% CI and precision verified?

Required materials and conditions: The reported direct effect, 95% CI, variance and denominator for nausea within 24 h
Conditions for verification: Distinguish P=.042 and the existing RR calculation from the unverified original interval.
Requirement and applicability: Required
Application exceptions: New intervals calculated from event counts or precision claims from a sample of 120 alone: 0.
Why this condition is needed: Distinguish P=.042 and the existing RR calculation from the unverified original interval. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N26 · What defines clinical importance of the incidence difference?

Required materials and conditions: Clinical-importance criteria and reported intervals for the relevant surgery/anesthesia and population
Conditions for verification: Do not invent a minimum difference or sufficiency threshold without justified criteria and an interval.
Requirement and applicability: Required
Application exceptions: Do not create individual preoperative dosing instructions or recommend replacing prophylactic drugs.
Why this condition is needed: Do not invent a minimum difference or sufficiency threshold without justified criteria and an interval. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N27 · Is there independent replication for the same surgery, anesthesia, formulation and nausea outcome within 24 h?

Required materials and conditions: Original-trial families, research teams and trial-specific results matching the conditions
Conditions for verification: Distinguish a review's repeated direction from unverified independent replication under the same conditions.
Requirement and applicability: Required
Application exceptions: Do not count 14 RCTs as 14 independent same-condition replications.
Why this condition is needed: Distinguish a review's repeated direction from unverified independent replication under the same conditions. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N28 · Does the evidence establish other doses, repeated dosing or optimal timing?

Required materials and conditions: Direct dose/timing and repeated-regimen comparisons using the same powder formulation
Conditions for verification: Separate the current single 1 g dose given 1 h before surgery from optimal-dose/timing claims.
Requirement and applicability: Supplementary; required for optimal-condition claims
Application exceptions: Do not rank dose effects across different studies as direct superiority comparisons.
Why this condition is needed: Separate the current single 1 g dose given 1 h before surgery from optimal-dose/timing claims. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N29 · Does the evidence answer outcomes beyond 24 h or in other populations?

Required materials and conditions: Delayed nausea after cessation, long-term outcomes, special populations and other anesthesia
Conditions for verification: Separate acute observation over 24 h from gaps about persistence, harms and other populations.
Requirement and applicability: Supplementary; required for persistence/extensions
Application exceptions: Do not require every long-term question as a necessary condition for the narrow question within 24 h.
Why this condition is needed: Separate acute observation over 24 h from gaps about persistence, harms and other populations. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N30 · Does a nausea result establish vomiting/aspiration prevention or replacement of prophylaxis?

Required materials and conditions: Direct outcomes for nausea incidence, vomiting, aspiration and prophylaxis replacement
Conditions for verification: Do not expand a selected symptom result into clinical-event prevention or drug replacement.
Requirement and applicability: Supplementary; required for extension claims
Application exceptions: Do not automatically require aspiration-event trials to identify the nausea question within 24 h.
Why this condition is needed: Do not expand a selected symptom result into clinical-event prevention or drug replacement. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N31 · Which harms were collected in the direct trial?

Required materials and conditions: Adverse-event definitions, collection and discontinuation around surgery after a single 1 g powder dose
Conditions for verification: Separate nausea-prevention efficacy from collection of ginger-attributed harms.
Requirement and applicability: Supplementary; required for safety claims
Application exceptions: An efficacy table or caution advice does not replace a complete adverse-event tally.
Why this condition is needed: Separate nausea-prevention efficacy from collection of ginger-attributed harms. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N32 · What level of information is the fasting/aspiration caution?

Required materials and conditions: Original fasting/aspiration caution, actual administration, aspiration events and anesthesia-team decisions
Conditions for verification: Do not turn caution advice into a risk incidence or ginger's aspiration-prevention effect.
Requirement and applicability: Supplementary
Application exceptions: Do not transfer the trial dose into instructions to self-administer before surgery.
Why this condition is needed: Do not turn caution advice into a risk incidence or ginger's aspiration-prevention effect. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N33 · Are harms with anticoagulant/antiplatelet use verified?

Required materials and conditions: Concomitant drugs, baseline risk, bleeding/interactions and exposure data
Conditions for verification: Distinguish original caution advice from unverified interaction/harm magnitudes.
Requirement and applicability: Supplementary; required for the specified harm claim
Application exceptions: Do not estimate new bleeding rates or interaction effects or establish safety.
Why this condition is needed: Distinguish original caution advice from unverified interaction/harm magnitudes. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N34 · Are harm denominators and observation losses verified?

Required materials and conditions: Arm-specific people/events with harms, exposure time, collection, missingness and discontinuation
Conditions for verification: Distinguish nausea event denominators from denominators for overall harms, bleeding or aspiration incidence.
Requirement and applicability: Supplementary; required for incidence claims
Application exceptions: Do not read 29/60 versus 40/60 as denominators/incidence for ginger-attributed adverse effects.
Why this condition is needed: Distinguish nausea event denominators from denominators for overall harms, bleeding or aspiration incidence. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N35 · Are efficacy comparisons distinguished from harm signals and causation?

Required materials and conditions: The placebo comparison of nausea within 24 h and separate harm, timing, alternative-cause and safety scopes
Conditions for verification: Do not reverse comparative nausea reduction into a signal that ginger causes nausea.
Requirement and applicability: Required boundary
Application exceptions: Do not use historical C46/caution/cross-check wording as a new efficacy/safety grade or independent clinical certification.
Why this condition is needed: Do not reverse comparative nausea reduction into a signal that ginger causes nausea. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N36 · Are review PROSPERO registration and direct-trial registration distinguished?

Required materials and conditions: Unverified direct-trial registration, Chen review CRD42020220916 and linked plans
Conditions for verification: Do not substitute a review registration number for preregistration/endpoints of the original gynecologic trial.
Requirement and applicability: Required
Application exceptions: Unacquired registration information does not prove nonregistration or selective reporting.
Why this condition is needed: Do not substitute a review registration number for preregistration/endpoints of the original gynecologic trial. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

N37 · What information do generic English evidence-table wording, past corrections and the two languages provide?

Required materials and conditions: Generic original English participant/funding/endpoint/result/weight wording and the correction statement dated 2026-09-14
Conditions for verification: Retain actual Korean/English values and the correction statement; do not use generic wording as new verification of denominators, company relationships or results.
Requirement and applicability: Required boundary
Application exceptions: Do not overwrite retained English evidence or record a new correction/reassessment because of the reader translation.
Why this condition is needed: Retain actual Korean/English values and the correction statement; do not use generic wording as new verification of denominators, company relationships or results. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.
Extent of review: Retained method-application records were reused. External originals were not reread and method content was not reassessed.

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish studies from reports and link them; do not omit a study solely because results are unreported.
Extent of review: Retained method-application records were reused. External originals were not reread and method content was not reassessed.

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.
Extent of review: Retained method-application records were reused. External originals were not reread and method content was not reassessed.

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review: Retained method-application records were reused. External originals were not reread and method content was not reassessed.

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.
Extent of review: Retained method-application records were reused. External originals were not reread and method content was not reassessed.

What the statuses mean

Partly verified: Partial information from the stored summary is linked; detailed originals and content review remain incomplete.
Unverified: Required details cannot be established within the preserved scope. This does not establish absence of effects or studies, or safety.
Review incomplete: Review of existing content remains incomplete.
Met: The selected condition for material, identity or preservation was verified; this does not establish efficacy success or independent clinical validation.
Not reported: Unreported within material actually read. Unread external material is not relabeled as unreported.
Inaccessible: This means actual access failure. External access was not attempted in this work, so this state was not assigned.
Not applicable: Used only with an application exception and reason based on the question scope.
Conflicting data: This requires actual comparison of materials; no new conflict judgment was made in this work.
Insufficient evidence for the conditions: This indicates gaps in additional material for the selected conditions. Unread material as a whole is not converted into an efficacy grade.

Change history

2026-10-25 · Public page/material version 1.0

The public view and materials were prepared from the existing 37 items. No new clinical search, verification-state change or scoring was performed.

The stored-material review date (2026-10-06) and original evidence cut-off (2026-09-08) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · Which independent postoperative-nausea question is covered?

Current findings: The original question concerns ASA I–II adult women having major gynecologic laparotomy under general anesthesia, with 1 g of powder given once 1 h before surgery and nausea incidence assessed over 24 h. The selected endpoint is the proportion reporting any nausea.
Verification status: Met
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: The formulation, population, comparison, endpoint and time are identifiable in the retained original.
Reason for missing information: Prespecified primary (1st) status, the original CI and independent replication are separate from identifying this boundary.
Required materials and conditions: ASA I–II adult women; major gynecologic laparotomy/general anesthesia; 1 g given 1 h before surgery; placebo comparison of any nausea within 24 h
Materials to obtain first: Original reports, plans and linked documents for ASA I–II adult women; major gynecologic laparotomy/general anesthesia; 1 g given 1 h before surgery; placebo comparison of any nausea within 24 h. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for ASA I–II adult women; major gynecologic laparotomy/general anesthesia; 1 g given 1 h before surgery; placebo comparison of any nausea within 24 h. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: Verification of question identity does not confirm efficacy.
Conditions for verification: Link the original question to the proportion reporting any nausea within 24 h.
Why this condition is needed: Link the original question to the proportion reporting any nausea within 24 h. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: Do not combine nausea severity, vomiting, composite PONV or rescue medication into an independent primary effect.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01 R02

N02 · Do the direct and synthesis reports count the same trials more than once?

Current findings: The structured record contains the direct Nanthakomon 2006 report and the Chen 2022 review. The direct 120 participants and the review's 14 RCTs/1506 participants are not added together; unique trial and participant totals remain unverified.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: Report identities are retained, but review inclusion, overlap and trial-family/team relationships remain unresolved.
Reason for missing information: Included trials, registration and unique trial-family/participant counts are unverified.
Required materials and conditions: The 2006 gynecologic-surgery report, the Chen 2022 review's inclusion table and trial identifiers
Materials to obtain first: Original reports, plans and linked documents for The 2006 gynecologic-surgery report, the Chen 2022 review's inclusion table and trial identifiers. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for The 2006 gynecologic-surgery report, the Chen 2022 review's inclusion table and trial identifiers. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: 2 reports do not establish 2 independent studies or a combined participant total.
Conditions for verification: Distinguish report/trial families for the direct 120 participants and the review's 14 RCTs/1506 participants without adding them together.
Why this condition is needed: Distinguish report/trial families for the direct 120 participants and the review's 14 RCTs/1506 participants without adding them together. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: Do not count a review, its original trials or repeated endpoint/time-point citations as independent replication.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01 R02

N03 · Are actual reading and the existence of external material distinguished?

Current findings: The full retained record and report/bibliographic summaries were read. External PubMed pages/abstracts, full texts, registration, protocols and SAPs were not opened.
Verification status: Met
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: Actual summary reading and unread external material are separated.
Reason for missing information: Public availability, acquisition and actual external contents remain unverified.
Required materials and conditions: Reading/acquisition histories for the retained record, PubMed bibliography/abstract, full text, registration, protocol and SAP
Materials to obtain first: Original reports, plans and linked documents for Reading/acquisition histories for the retained record, PubMed bibliography/abstract, full text, registration, protocol and SAP. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for Reading/acquisition histories for the retained record, PubMed bibliography/abstract, full text, registration, protocol and SAP. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: The current record has no access-level field; historical verification dates are not used as new reading dates.
Conditions for verification: Display current reading of the stored summary separately from unread external material.
Why this condition is needed: Display current reading of the stored summary separately from unread external material. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: A URL or the original verdict date does not establish full-text reading in this work.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01 R02

N04 · What surgery, anesthesia and adult-women population is covered?

Current findings: The original population is ASA I–II adult women having elective major gynecologic laparotomy under general anesthesia. Detailed eligibility/exclusion, baseline PONV risk and the anesthesia regimen are not provided in the summary.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: Population, surgery and anesthesia names are retained; actual eligibility and baseline conditions need further material.
Reason for missing information: Eligibility/exclusion, baseline risk and detailed anesthesia are unverified.
Required materials and conditions: Eligibility/exclusion for ASA I–II adult women undergoing elective major gynecologic laparotomy under general anesthesia
Materials to obtain first: Original reports, plans and linked documents for Eligibility/exclusion for ASA I–II adult women undergoing elective major gynecologic laparotomy under general anesthesia. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for Eligibility/exclusion for ASA I–II adult women undergoing elective major gynecologic laparotomy under general anesthesia. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: Do not automatically apply the result to cesarean delivery, other surgery/anesthesia or other populations.
Conditions for verification: Distinguish the direct population from cesarean delivery, other surgery/anesthesia, other sexes and baseline conditions.
Why this condition is needed: Distinguish the direct population from cesarean delivery, other surgery/anesthesia, other sexes and baseline conditions. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: A shared postoperative-nausea label does not justify transfer to every population.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01 R02

N05 · What dried ginger-powder formulation and product specifications are recorded?

Current findings: The formulation is 2 capsules of 500 mg dried ginger powder; the retained funding description names Khao-la-o Laboratories powder. Quantification/manufacturing specifications and the supply role lack detail.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: Product/formulation identity is distinguished from standardization and support facts.
Reason for missing information: Ingredient quantification, manufacturing specifications and actual supply/support documents are unverified.
Required materials and conditions: Rhizome, 2 capsules of 500 mg, Khao-la-o powder and ingredient quantification
Materials to obtain first: Original reports, plans and linked documents for Rhizome, 2 capsules of 500 mg, Khao-la-o powder and ingredient quantification. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for Rhizome, 2 capsules of 500 mg, Khao-la-o powder and ingredient quantification. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: A brand name does not verify company funding, free supply or employee authorship.
Conditions for verification: Distinguish the dried-powder formulation and brand wording from verification of standardization/product support.
Why this condition is needed: Distinguish the dried-powder formulation and brand wording from verification of standardization/product support. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: Do not turn a product name into evidence of an extract, company funding or free supply.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01

N06 · Are a single 1 g dose 1 hour before surgery and follow-up distinguished?

Current findings: The original regimen is a single oral 1 g dose (2 capsules of 500 mg) given 1 hour before surgery, with 24 h follow-up. Actual ingestion, adherence and timing deviations are not established in the summary.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: Nominal administration and follow-up are recorded; actual implementation remains unverified.
Reason for missing information: Actual administration records, adherence and deviations are unverified.
Required materials and conditions: One 1 g dose (2 capsules of 500 mg), given 1 h before surgery; 24 h follow-up; actual administration/adherence
Materials to obtain first: Original reports, plans and linked documents for One 1 g dose (2 capsules of 500 mg), given 1 h before surgery; 24 h follow-up; actual administration/adherence. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for One 1 g dose (2 capsules of 500 mg), given 1 h before surgery; 24 h follow-up; actual administration/adherence. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: Do not copy the same effect to repeated dosing or other timings.
Conditions for verification: Record dose, timing and frequency separately from postoperative observation duration.
Why this condition is needed: Record dose, timing and frequency separately from postoperative observation duration. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: Do not fill other doses or repeated regimens with the same effect estimate.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01

N07 · What placebo and common anesthesia/rescue treatment are described?

Current findings: The comparison specifies appearance- and odor-matched lactose placebo and the same anesthesia/rescue care. Drugs, doses, actual use and arm-specific handling lack detail in the current summary.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: A placebo/common-care statement is distinct from verifying actual concomitant treatment methods.
Reason for missing information: Anesthesia/rescue treatment, concomitant care and handling of arm-specific deviations are unverified.
Required materials and conditions: Actual contents of appearance- and odor-matched lactose placebo and the same anesthesia/rescue care
Materials to obtain first: Original reports, plans and linked documents for Actual contents of appearance- and odor-matched lactose placebo and the same anesthesia/rescue care. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for Actual contents of appearance- and odor-matched lactose placebo and the same anesthesia/rescue care. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: Matching appearance/odor does not establish successful complete blinding or identical care throughout.
Conditions for verification: Distinguish planned common care from actual drugs, administration, rescue-treatment differences and handling.
Why this condition is needed: Distinguish planned common care from actual drugs, administration, rescue-treatment differences and handling. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: Matching appearance/odor does not verify every blinding procedure or every concomitant treatment.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01

N08 · What outcome is nausea incidence within 24 hours?

Current findings: The selected endpoint is the proportion reporting any nausea within 24 h. The direct summary assigns 29/60 versus 40/60 and P=.042 to this outcome.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: The incidence contract and reported values are retained; collection/definition and prespecification details remain unresolved.
Reason for missing information: Original collection methods, prespecified hierarchy and denominator status are unverified.
Required materials and conditions: Definition and collection of the proportion reporting any nausea within 24 h
Materials to obtain first: Original reports, plans and linked documents for Definition and collection of the proportion reporting any nausea within 24 h. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for Definition and collection of the proportion reporting any nausea within 24 h. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: Do not equate this with nausea episodes, severity, vomiting or composite PONV.
Conditions for verification: Distinguish events/denominators for a patient proportion from nausea episodes, scores and vomiting.
Why this condition is needed: Distinguish events/denominators for a patient proportion from nausea episodes, scores and vomiting. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: The page's selected endpoint does not establish that it was a preregistered primary (1st) endpoint.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01

N09 · Are scores/severity at 2, 6 and 12 hours the same outcome?

Current findings: The review reports a positive direction in nausea scores at 2, 6 and 12 h, while the Korean narrative describes reduced nausea severity. These measures/time points differ from the proportion affected within 24 h.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: Time-specific score directions are retained; scales, denominators and trial-specific original results remain unverified.
Reason for missing information: Score/severity definitions, times and included-trial estimates are unverified.
Required materials and conditions: Definitions, denominators and scales for the review's nausea scores/severity at 2/6/12 h
Materials to obtain first: Original reports, plans and linked documents for Definitions, denominators and scales for the review's nausea scores/severity at 2/6/12 h. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for Definitions, denominators and scales for the review's nausea scores/severity at 2/6/12 h. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: Do not transfer scores into direct 24 h event counts or effect estimates.
Conditions for verification: Attribute positive time-specific score directions to a measure distinct from the proportion affected within 24 h.
Why this condition is needed: Attribute positive time-specific score directions to a measure distinct from the proportion affected within 24 h. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: Do not turn scores into 24 h event counts or effects from the direct original trial.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R02

N10 · Are vomiting, composite PONV and rescue-medication outcomes separated?

Current findings: The review summary reports null incidence results for vomiting, composite PONV and rescue medication; the Korean narrative describes these as mostly null. They remain separate endpoints from nausea incidence within 24 h.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: Unfavorable/no-difference directions for other endpoints are retained; endpoint-specific estimates and times remain unverified.
Reason for missing information: Definitions, denominators and estimates for vomiting/composite/rescue outcomes are unverified.
Required materials and conditions: Definitions, times and denominators for each outcome, and the review's null-result statements
Materials to obtain first: Original reports, plans and linked documents for Definitions, times and denominators for each outcome, and the review's null-result statements. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for Definitions, times and denominators for each outcome, and the review's null-result statements. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: A null statement is not an effect of 0, equivalence or denial of the nausea-incidence benefit within 24 h.
Conditions for verification: Retain nausea-benefit statements alongside null statements for other endpoints.
Why this condition is needed: Retain nausea-benefit statements alongside null statements for other endpoints. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: Do not replace null/nonsignificant findings with an effect of 0, equivalence or absence of a nausea result within 24 h.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R02

N11 · What denominators do 120 participants, 60/60 and 29/60 versus 40/60 represent?

Current findings: The original sample is 120 participants, 60/60, with nausea within 24 h in 29/60 versus 40/60. Detailed flow is needed to establish whether allocated, completed, measured and analyzed denominators coincide.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: Only stored event counts/denominators are retained; further participant counts or denominator meanings are not established.
Reason for missing information: Actual allocated/completed/observed/analyzed counts and participant flow are unverified.
Required materials and conditions: Allocated/completed/analyzed participants and patients experiencing nausea within 24 h
Materials to obtain first: Original reports, plans and linked documents for Allocated/completed/analyzed participants and patients experiencing nausea within 24 h. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for Allocated/completed/analyzed participants and patients experiencing nausea within 24 h. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: Do not read event counts as nausea episodes or denominators for all harms.
Conditions for verification: Retain the original 120 participants, 60/60 and 29/60 versus 40/60 at the reported level.
Why this condition is needed: Retain the original 120 participants, 60/60 and 29/60 versus 40/60 at the reported level. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: Do not assume all allocated, completed, measured and analyzed denominators are identical.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01

N12 · Are missing data, withdrawals and analysis handling verified?

Current findings: The current summary does not specify arm-specific withdrawals, follow-up loss, missing-data handling, analysis populations or sensitivity analyses within 24 h.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: The 60/60 notation and generic English participant wording cannot establish complete follow-up or analysis handling.
Reason for missing information: Actual flow/missing-data handling is unspecified in the retained record; full text/SAP remain unread.
Required materials and conditions: Arm-specific observation loss within 24 h, withdrawal reasons, analysis populations and handling
Materials to obtain first: Original reports, plans and linked documents for Arm-specific observation loss within 24 h, withdrawal reasons, analysis populations and handling. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for Arm-specific observation loss within 24 h, withdrawal reasons, analysis populations and handling. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: Do not fill missing details with 0 withdrawals, complete follow-up or ITT.
Conditions for verification: Identify the need to verify actual follow-up/completion and missing-data handling beyond the original event denominators.
Why this condition is needed: Identify the need to verify actual follow-up/completion and missing-data handling beyond the original event denominators. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: No withdrawal/missing-data information does not establish 0 losses or complete follow-up.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01

N13 · Is the stored RR of about 0.725 an original-paper estimate?

Current findings: The original evidence and bibliography record 29/60 versus 40/60, P=.042 and a calculated RR of about 0.725, with the original 95% CI unverified. This RR is a retained historical calculation, not a new calculation in this work.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: Reported events, P and the provenance level of the existing calculation are distinguished; the original reported interval remains unresolved.
Reason for missing information: The original estimate/95% CI and direct linkage to the historical calculation receipt are unverified.
Required materials and conditions: 29/60 versus 40/60, P=.042 and the calculated-RR label in the original evidence/bibliography
Materials to obtain first: Original reports, plans and linked documents for 29/60 versus 40/60, P=.042 and the calculated-RR label in the original evidence/bibliography. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for 29/60 versus 40/60, P=.042 and the calculated-RR label in the original evidence/bibliography. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: Do not promote this to an original-paper RR or calculate a new RR/RD/NNT/CI.
Conditions for verification: Label the RR of about 0.725 only as a stored historical calculation and retain the unverified original 95% CI.
Why this condition is needed: Label the RR of about 0.725 only as a stored historical calculation and retain the unverified original 95% CI. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: Do not calculate a new RR/RD/NNT/CI or promote the stored value to an original-paper estimate.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01

N14 · How are other surgery and cesarean-delivery findings retained?

Current findings: The Korean/English narratives describe very low certainty and an unestablished nausea benefit in a cesarean-only Cochrane analysis. The structured bibliography contains no separate Cochrane citation or inclusion table.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: Opposing/uncertain background is retained without counting it as direct replication under the same surgery/anesthesia.
Reason for missing information: The cesarean citation, surgery/anesthesia-specific included trials and exact results are unverified.
Required materials and conditions: Other surgery/anesthesia, cesarean-only Cochrane statements and differences from the direct question
Materials to obtain first: Original reports, plans and linked documents for Other surgery/anesthesia, cesarean-only Cochrane statements and differences from the direct question. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for Other surgery/anesthesia, cesarean-only Cochrane statements and differences from the direct question. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: A result from other surgery does not establish a conflict on the identical direct gynecologic-laparotomy question within 24 h.
Conditions for verification: Keep cesarean-only statements of very low certainty and unestablished nausea benefit in a separate context.
Why this condition is needed: Keep cesarean-only statements of very low certainty and unestablished nausea benefit in a separate context. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: Do not add other surgeries as independent replications under the same gynecologic laparotomy/general-anesthesia conditions.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01 R02

N15 · What do the Korean 2021 narrative, Chen 2022 citation and dates mean?

Current findings: The original verdict date 2026-09-08, correction date 2026-09-14 and Korean/English narrative about two 2021 meta-analyses are retained. The explicit citation is Chen 2022; no collection year was inferred. New clinical searches in this work: 0.
Verification status: Met
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: Narrative year, citation year, original verdict date and current review are distinguished.
Reason for missing information: Complete bibliographic links for the two 2021 narrative references and current publication/retraction status are unverified.
Required materials and conditions: The Korean/English narrative about two 2021 meta-analyses, the explicit Chen 2022 citation and original verdict/correction dates
Materials to obtain first: Original reports, plans and linked documents for The Korean/English narrative about two 2021 meta-analyses, the explicit Chen 2022 citation and original verdict/correction dates. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for The Korean/English narrative about two 2021 meta-analyses, the explicit Chen 2022 citation and original verdict/correction dates. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: Do not invent further studies/reports beyond the 2 explicit citations.
Conditions for verification: Retain narrative years and citation publication years without inferring collection years or additional reports.
Why this condition is needed: Retain narrative years and citation publication years without inferring collection years or additional reports. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: No new search does not mean 0 studies or verification of current publication/retraction status.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01 R02

N16 · How far are research funding sources verified?

Current findings: The direct funding description says the funding source is unverified; the review describes mixed original-trial funding. The Khao-la-o brand or historical I1 axis is not an original declaration of independent funding.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: Specific sources/company roles remain unverified beyond report-specific funding statements.
Reason for missing information: Original funding/company-role documents are unverified.
Required materials and conditions: The direct trial's funding/company role and funding of original trials in the review
Materials to obtain first: Original reports, plans and linked documents for The direct trial's funding/company role and funding of original trials in the review. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for The direct trial's funding/company role and funding of original trials in the review. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: Do not fill the gap with confirmed independent funding or confirmed company funding.
Conditions for verification: Distinguish the direct trial's unverified funding source from mixed funding statements about the review's original trials.
Why this condition is needed: Distinguish the direct trial's unverified funding source from mixed funding statements about the review's original trials. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: Historical I1 or a product name does not verify independent funding.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01 R02

N17 · Are product supply and support verified?

Current findings: The original funding description names Khao-la-o Laboratories powder but does not specify actual supply/free-support scope or roles.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: A product name is distinguished from verification of provision/support.
Reason for missing information: Original product-supply/support/company-role documents are unverified.
Required materials and conditions: Declarations about Khao-la-o powder supply, free provision and roles
Materials to obtain first: Original reports, plans and linked documents for Declarations about Khao-la-o powder supply, free provision and roles. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for Declarations about Khao-la-o powder supply, free provision and roles. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: Do not replace this with no support or confirmed free supply.
Conditions for verification: Record the product brand separately from actual supply/support scope.
Why this condition is needed: Record the product brand separately from actual supply/support scope. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: A named product does not establish free supply or absence of support.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01

N18 · Are employee authorship and research teams verified?

Current findings: The retained summary contains no concrete finding on company employment, affiliations or author contributions. The English funding description only contains generic wording about separate assessment of employee authorship and related matters.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: There is no original record verifying employee-authorship presence/absence or independent-team relationships.
Reason for missing information: Author employment, affiliations and team relationships are unverified.
Required materials and conditions: Author affiliations, company employment and team/report-family relationships
Materials to obtain first: Original reports, plans and linked documents for Author affiliations, company employment and team/report-family relationships. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for Author affiliations, company employment and team/report-family relationships. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: Do not promote a review's repeated direction into verified independent teams or same-condition replication.
Conditions for verification: Do not use generic English wording to fill employee-authorship or independent-team presence/absence.
Why this condition is needed: Do not use generic English wording to fill employee-authorship or independent-team presence/absence. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: A review's repeated direction does not establish same-condition replication by a different independent research team.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01 R02

N19 · How far are declared conflicts and patents verified?

Current findings: The current retained record lacks detailed original conflict-of-interest/patent declarations. Generic English funding wording and I1 are retained without treating them as declaration documents.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: Presence or absence of conflicts cannot be established without comparing original declarations and their scope.
Reason for missing information: Declared conflicts, patents and institutional roles are unverified.
Required materials and conditions: Author/institution declarations of interests, patents and product roles
Materials to obtain first: Original reports, plans and linked documents for Author/institution declarations of interests, patents and product roles. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for Author/institution declarations of interests, patents and product roles. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: Do not invent no conflicts, no bias or a new independence grade.
Conditions for verification: Do not label unread/unverified declarations as no conflicts or no bias.
Why this condition is needed: Do not label unread/unverified declarations as no conflicts or no bias. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: Historical axes, brands and generic English funding wording do not replace declaration documents.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01 R02

N20 · What randomization, concealment and blinding were actually used?

Current findings: The direct study is described as randomized, double-blind and placebo-controlled, with appearance- and odor-matched lactose placebo. Sequence generation, concealment, actual assessor blinding and baseline-risk details are absent.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: The design label/placebo features are retained; actual allocation/blinding methods still need comparison.
Reason for missing information: Random sequence generation, concealment, blinding and baseline balance are unverified.
Required materials and conditions: Sequence generation, concealment, assessors and baseline differences in the double-blind placebo trial
Materials to obtain first: Original reports, plans and linked documents for Sequence generation, concealment, assessors and baseline differences in the double-blind placebo trial. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for Sequence generation, concealment, assessors and baseline differences in the double-blind placebo trial. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: A design label or matched odor does not establish absence of bias.
Conditions for verification: Distinguish the design label from actual method verification and retain unverified limitations.
Why this condition is needed: Distinguish the design label from actual method verification and retain unverified limitations. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: Matched placebo appearance/odor does not verify every blinding procedure.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01

N21 · Could anesthesia, prophylaxis or rescue-care differences obscure the intervention's contribution?

Current findings: The original comparison states the same anesthesia/rescue care. Actual administration, arm-specific use and handling of anesthetics, prophylactic antiemetics and rescue medication lack detail.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: A common-care statement is separate from differences/deviations in actual concurrent interventions.
Reason for missing information: Drugs, administration, rescue use and adherence/analysis handling are unverified.
Required materials and conditions: Arm-specific anesthetics, prophylactic antiemetics, rescue care, adherence/deviations and handling
Materials to obtain first: Original reports, plans and linked documents for Arm-specific anesthetics, prophylactic antiemetics, rescue care, adherence/deviations and handling. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for Arm-specific anesthetics, prophylactic antiemetics, rescue care, adherence/deviations and handling. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: Do not turn rescue-medication results or concomitant-treatment differences into a ginger-only effect.
Conditions for verification: Distinguish a same-anesthesia/rescue-care statement from unverified actual administration and analysis backgrounds.
Why this condition is needed: Distinguish a same-anesthesia/rescue-care statement from unverified actual administration and analysis backgrounds. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: Do not transfer rescue endpoints or concomitant-treatment differences into the effect of ginger alone.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01 R02

N22 · Who collected nausea, when and with which scale?

Current findings: The current scope specifies the proportion reporting any nausea within 24 h. The summary lacks detail on who assessed it, when, which question/scale was used and assessor blinding/recall.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: The incidence definition is retained; actual measurement procedures and missingness remain unresolved.
Reason for missing information: Assessors, collection times, scales and recall/blinding are unverified.
Required materials and conditions: Questions, assessor blinding, visits, recall and severity measurement for any nausea within 24 h
Materials to obtain first: Original reports, plans and linked documents for Questions, assessor blinding, visits, recall and severity measurement for any nausea within 24 h. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for Questions, assessor blinding, visits, recall and severity measurement for any nausea within 24 h. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: Do not substitute incidence, severity and scores or assume complete collection.
Conditions for verification: Attribute patient incidence and score/severity measures to their actual collection methods.
Why this condition is needed: Attribute patient incidence and score/severity measures to their actual collection methods. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: Do not fill unread details with complete collection, objective measurement or validated scales.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01 R02

N23 · Which intervention effect does the 24 h analysis estimate?

Current findings: Event comparisons are reported, but assignment/adherence effects, ITT/PP, adjustment and actual analysis populations/models are not specified in the retained summary.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: An event denominator of 60 cannot establish the analysis plan or effect of interest.
Reason for missing information: The effect of interest, analysis plan, populations and models are unverified.
Required materials and conditions: Assignment/adherence effects, ITT/PP, adjustment and analysis populations/models
Materials to obtain first: Original reports, plans and linked documents for Assignment/adherence effects, ITT/PP, adjustment and analysis populations/models. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for Assignment/adherence effects, ITT/PP, adjustment and analysis populations/models. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: New reanalyses or arbitrary ITT/PP designations: 0.
Conditions for verification: Distinguish reported event comparisons from verification of actual analysis definitions.
Why this condition is needed: Distinguish reported event comparisons from verification of actual analysis definitions. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: A denominator of 60 does not justify choosing ITT/PP or performing a new analysis.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01

N24 · Was nausea alone a prespecified primary (1st) endpoint?

Current findings: The original reader answer says prespecified primary (1st) status for nausea alone is unverified; trial registration is recorded as unverified.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: The current nausea outcome within 24 h is distinguished from a preregistered hierarchy; comparison material remains needed.
Reason for missing information: Original registration, protocol, SAP and prespecified endpoints/multiplicity are unverified.
Required materials and conditions: Endpoints, times and multiplicity in direct-trial registration, protocol and SAP
Materials to obtain first: Original reports, plans and linked documents for Endpoints, times and multiplicity in direct-trial registration, protocol and SAP. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for Endpoints, times and multiplicity in direct-trial registration, protocol and SAP. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: Neither a significant P nor the page's selected endpoint proves a prespecified primary (1st) success.
Conditions for verification: Retain the selected nausea outcome within 24 h alongside unverified prespecified primary (1st) status.
Why this condition is needed: Retain the selected nausea outcome within 24 h alongside unverified prespecified primary (1st) status. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: A reported significant P does not prove a prespecified primary (1st) success.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01

N25 · Are the original between-group 95% CI and precision verified?

Current findings: The original result records P=.042 and an existing calculated RR of about 0.725; the original 95% CI remains unverified.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: Without the original reported interval, precision and the range of compatible effect sizes cannot be established.
Reason for missing information: The direct original effect, 95% CI and variance/denominator definitions are unverified.
Required materials and conditions: The reported direct effect, 95% CI, variance and denominator for nausea within 24 h
Materials to obtain first: Original reports, plans and linked documents for The reported direct effect, 95% CI, variance and denominator for nausea within 24 h. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for The reported direct effect, 95% CI, variance and denominator for nausea within 24 h. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: New CI calculations or precision judgments from 120 participants alone: 0.
Conditions for verification: Distinguish P=.042 and the existing RR calculation from the unverified original interval.
Why this condition is needed: Distinguish P=.042 and the existing RR calculation from the unverified original interval. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: New intervals calculated from event counts or precision claims from a sample of 120 alone: 0.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01

N26 · What defines clinical importance of the incidence difference?

Current findings: The current retained record has no justified clinical-importance threshold or original interval for a difference in nausea incidence within 24 h in this surgery/anesthesia and population.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: Material to compare the reported interval with clinical-importance evidence remains unverified.
Reason for missing information: Clinical-importance criteria and the original interval are unverified.
Required materials and conditions: Clinical-importance criteria and reported intervals for the relevant surgery/anesthesia and population
Materials to obtain first: Original reports, plans and linked documents for Clinical-importance criteria and reported intervals for the relevant surgery/anesthesia and population. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for Clinical-importance criteria and reported intervals for the relevant surgery/anesthesia and population. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: Do not invent minimum differences, sufficiency or individual dosing/prophylaxis-replacement recommendations.
Conditions for verification: Do not invent a minimum difference or sufficiency threshold without justified criteria and an interval.
Why this condition is needed: Do not invent a minimum difference or sufficiency threshold without justified criteria and an interval. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: Do not create individual preoperative dosing instructions or recommend replacing prophylactic drugs.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01

N27 · Is there independent replication for the same surgery, anesthesia, formulation and nausea outcome within 24 h?

Current findings: The original narrative leaves same-condition independent replication unverified. The review's 14 RCTs do not establish 14 replications with the same surgery/anesthesia, endpoint and time.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: Trial-specific conditions, registration/families and team identities are not retained.
Reason for missing information: Same-condition trials/teams and the distribution of trial-specific results are unverified.
Required materials and conditions: Original-trial families, research teams and trial-specific results matching the conditions
Materials to obtain first: Original reports, plans and linked documents for Original-trial families, research teams and trial-specific results matching the conditions. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for Original-trial families, research teams and trial-specific results matching the conditions. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: Do not add an original trial to a review or to score results at other times.
Conditions for verification: Distinguish a review's repeated direction from unverified independent replication under the same conditions.
Why this condition is needed: Distinguish a review's repeated direction from unverified independent replication under the same conditions. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: Do not count 14 RCTs as 14 independent same-condition replications.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01 R02

N28 · Does the evidence establish other doses, repeated dosing or optimal timing?

Current findings: The current direct question is a single 1 g powder dose given 1 h before surgery. The retained summary contains no direct superiority comparison of doses, timings or repeated regimens of the same formulation.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: The selected regimen is separated from extension claims about optimal conditions.
Reason for missing information: Direct dose/timing/repeated-regimen comparisons are unverified.
Required materials and conditions: Direct dose/timing and repeated-regimen comparisons using the same powder formulation
Materials to obtain first: Original reports, plans and linked documents for Direct dose/timing and repeated-regimen comparisons using the same powder formulation. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for Direct dose/timing and repeated-regimen comparisons using the same powder formulation. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: Do not interpret dose effects from different studies as direct superiority evidence.
Conditions for verification: Separate the current single 1 g dose given 1 h before surgery from optimal-dose/timing claims.
Why this condition is needed: Separate the current single 1 g dose given 1 h before surgery from optimal-dose/timing claims. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: Do not rank dose effects across different studies as direct superiority comparisons.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01

N29 · Does the evidence answer outcomes beyond 24 h or in other populations?

Current findings: Follow-up is 24 h, and the original narrative rejects equal benefit in every surgery. Delayed nausea, long-term outcomes and special-population follow-up are unverified in the summary.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: The acute time window is distinguished from gaps in extension questions.
Reason for missing information: Direct follow-up beyond 24 h or in other populations/anesthesia is unverified.
Required materials and conditions: Delayed nausea after cessation, long-term outcomes, special populations and other anesthesia
Materials to obtain first: Original reports, plans and linked documents for Delayed nausea after cessation, long-term outcomes, special populations and other anesthesia. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for Delayed nausea after cessation, long-term outcomes, special populations and other anesthesia. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: Do not force every long-term trial question into the narrow acute question.
Conditions for verification: Separate acute observation over 24 h from gaps about persistence, harms and other populations.
Why this condition is needed: Separate acute observation over 24 h from gaps about persistence, harms and other populations. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: Do not require every long-term question as a necessary condition for the narrow question within 24 h.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01

N30 · Does a nausea result establish vomiting/aspiration prevention or replacement of prophylaxis?

Current findings: The original scope note assesses nausea incidence within 24 h and separates vomiting/composite PONV. The advertising limits exclude prophylactic-antiemetic replacement, vomiting/aspiration prevention and equal effects in every surgery.
Verification status: Met
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: The boundary between the selected symptom and separate event/drug-replacement questions is explicitly retained.
Reason for missing information: Direct aspiration/prophylaxis-replacement results are unverified within this scope.
Required materials and conditions: Direct outcomes for nausea incidence, vomiting, aspiration and prophylaxis replacement
Materials to obtain first: Original reports, plans and linked documents for Direct outcomes for nausea incidence, vomiting, aspiration and prophylaxis replacement. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for Direct outcomes for nausea incidence, vomiting, aspiration and prophylaxis replacement. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: This verification does not establish extended efficacy or safety.
Conditions for verification: Do not expand a selected symptom result into clinical-event prevention or drug replacement.
Why this condition is needed: Do not expand a selected symptom result into clinical-event prevention or drug replacement. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: Do not automatically require aspiration-event trials to identify the nausea question within 24 h.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01 R02

N31 · Which harms were collected in the direct trial?

Current findings: The current retained record provides preoperative caution wording and nausea-prevention results but no detailed table of ginger-attributed adverse-event definitions, collection or discontinuation.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: Reduced nausea is different evidence from harm collection or a complete safety tally.
Reason for missing information: Direct harm details are unspecified in the retained record; external full text remains unread.
Required materials and conditions: Adverse-event definitions, collection and discontinuation around surgery after a single 1 g powder dose
Materials to obtain first: Original reports, plans and linked documents for Adverse-event definitions, collection and discontinuation around surgery after a single 1 g powder dose. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for Adverse-event definitions, collection and discontinuation around surgery after a single 1 g powder dose. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: Do not expand this to 0 harms, safety or whole-paper nonreporting.
Conditions for verification: Separate nausea-prevention efficacy from collection of ginger-attributed harms.
Why this condition is needed: Separate nausea-prevention efficacy from collection of ginger-attributed harms. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: An efficacy table or caution advice does not replace a complete adverse-event tally.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01

N32 · What level of information is the fasting/aspiration caution?

Current findings: The original safety advice prioritizes the anesthesia/surgical team's judgment about fasting/aspiration risk and says not to self-administer. Actual aspiration events and incidence denominators are absent from the summary.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: The caution is retained separately from risk incidence or aspiration-prevention efficacy.
Reason for missing information: Fasting/administration records and aspiration events, denominators and timing are unverified.
Required materials and conditions: Original fasting/aspiration caution, actual administration, aspiration events and anesthesia-team decisions
Materials to obtain first: Original reports, plans and linked documents for Original fasting/aspiration caution, actual administration, aspiration events and anesthesia-team decisions. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for Original fasting/aspiration caution, actual administration, aspiration events and anesthesia-team decisions. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: Do not turn the trial dose into personal preoperative dosing instructions.
Conditions for verification: Do not turn caution advice into a risk incidence or ginger's aspiration-prevention effect.
Why this condition is needed: Do not turn caution advice into a risk incidence or ginger's aspiration-prevention effect. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: Do not transfer the trial dose into instructions to self-administer before surgery.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01

N33 · Are harms with anticoagulant/antiplatelet use verified?

Current findings: The original advice prioritizes the surgical team's judgment for anticoagulant/antiplatelet use. Actual bleeding/interactions and concomitant-use denominators are unverified in the retained summary.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: Advice is different from verified effects or incidence of harms during concomitant use.
Reason for missing information: Direct event/exposure data on concomitant drugs, baseline risk and bleeding/interactions are unverified.
Required materials and conditions: Concomitant drugs, baseline risk, bleeding/interactions and exposure data
Materials to obtain first: Original reports, plans and linked documents for Concomitant drugs, baseline risk, bleeding/interactions and exposure data. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for Concomitant drugs, baseline risk, bleeding/interactions and exposure data. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: Do not infer risk magnitude, interaction effects or safety.
Conditions for verification: Distinguish original caution advice from unverified interaction/harm magnitudes.
Why this condition is needed: Distinguish original caution advice from unverified interaction/harm magnitudes. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: Do not estimate new bleeding rates or interaction effects or establish safety.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01

N34 · Are harm denominators and observation losses verified?

Current findings: Beyond the nausea event denominators of 29/60 versus 40/60, the current summary provides no overall harm, bleeding or aspiration events/exposure time or collection losses.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: An efficacy-endpoint denominator does not replace an incidence denominator for a separate harm.
Reason for missing information: Harm-specific events, denominators, time and collection/follow-up losses are unverified.
Required materials and conditions: Arm-specific people/events with harms, exposure time, collection, missingness and discontinuation
Materials to obtain first: Original reports, plans and linked documents for Arm-specific people/events with harms, exposure time, collection, missingness and discontinuation. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for Arm-specific people/events with harms, exposure time, collection, missingness and discontinuation. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: Do not reverse nausea-prevention event counts into frequencies of ginger-attributed adverse effects.
Conditions for verification: Distinguish nausea event denominators from denominators for overall harms, bleeding or aspiration incidence.
Why this condition is needed: Distinguish nausea event denominators from denominators for overall harms, bleeding or aspiration incidence. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: Do not read 29/60 versus 40/60 as denominators/incidence for ginger-attributed adverse effects.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01

N35 · Are efficacy comparisons distinguished from harm signals and causation?

Current findings: The current comparison concerns nausea-prevention efficacy against placebo. Original C46, caution, the historical I1/axes and cross-check wording are retained without converting them into ginger-caused nausea or a new safety judgment.
Verification status: Met
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: The direction of efficacy versus harm signals/causation and current interpretation limits are distinguished.
Reason for missing information: Separate harm comparisons, denominators, times and alternative causes remain unverified under the relevant conditions.
Required materials and conditions: The placebo comparison of nausea within 24 h and separate harm, timing, alternative-cause and safety scopes
Materials to obtain first: Original reports, plans and linked documents for The placebo comparison of nausea within 24 h and separate harm, timing, alternative-cause and safety scopes. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for The placebo comparison of nausea within 24 h and separate harm, timing, alternative-cause and safety scopes. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: Model self-review and original-byte/hash checks do not establish independent clinical certification.
Conditions for verification: Do not reverse comparative nausea reduction into a signal that ginger causes nausea.
Why this condition is needed: Do not reverse comparative nausea reduction into a signal that ginger causes nausea. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: Do not use historical C46/caution/cross-check wording as a new efficacy/safety grade or independent clinical certification.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01 R02

N36 · Are review PROSPERO registration and direct-trial registration distinguished?

Current findings: Direct-trial registration is unverified. PROSPERO CRD42020220916 in the Chen review citation is retained as review registration and is not used as preregistration of the original 2006 trial.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: Review/direct-trial identity levels are distinguished; actual registration/plan comparison remains unresolved.
Reason for missing information: Original-trial registration, review-registration contents/inclusion tables and protocols/SAPs remain unread.
Required materials and conditions: Unverified direct-trial registration, Chen review CRD42020220916 and linked plans
Materials to obtain first: Original reports, plans and linked documents for Unverified direct-trial registration, Chen review CRD42020220916 and linked plans. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for Unverified direct-trial registration, Chen review CRD42020220916 and linked plans. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: Unacquired material does not establish nonregistration or selective reporting.
Conditions for verification: Do not substitute a review registration number for preregistration/endpoints of the original gynecologic trial.
Why this condition is needed: Do not substitute a review registration number for preregistration/endpoints of the original gynecologic trial. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: Unacquired registration information does not prove nonregistration or selective reporting.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01 R02

N37 · What information do generic English evidence-table wording, past corrections and the two languages provide?

Current findings: Generic participant/funding/endpoint/result/weight wording remains in the current English evidence table; the correction reports replacement of 2 fields. The Korean/English text and correction statement are preserved in the original.
Verification status: Met
Materials actually read: The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.
Why unverified: Generic wording is distinguished from the actual original summary without using it as new denominator/company/result verification.
Reason for missing information: Details absent from generic wording remain unverified under the relevant conditions.
Required materials and conditions: Generic original English participant/funding/endpoint/result/weight wording and the correction statement dated 2026-09-14
Materials to obtain first: Original reports, plans and linked documents for Generic original English participant/funding/endpoint/result/weight wording and the correction statement dated 2026-09-14. First establish whether currently unverified material exists and has been acquired.
Further research: Material needed: Original reports, plans and linked documents for Generic original English participant/funding/endpoint/result/weight wording and the correction statement dated 2026-09-14. First establish whether currently unverified material exists and has been acquired. This records needed materials; no new research was executed.
Remaining uncertainty: Retain generic English and past corrections in the original; do not label a new reader translation as a correction applied to the original verdict.
Conditions for verification: Retain actual Korean/English values and the correction statement; do not use generic wording as new verification of denominators, company relationships or results.
Why this condition is needed: Retain actual Korean/English values and the correction statement; do not use generic wording as new verification of denominators, company relationships or results. Without this distinction, populations, endpoints and denominators for the selected nausea outcome within 24 h could be mixed with other results.
Application exceptions: Do not overwrite retained English evidence or record a new correction/reassessment because of the reader translation.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.

Related sources R01 R02